anchor.diff:            -  History of arterial or venous embolism within 3 months prior to study enrollment. If
                the embolism occurred >3 and <6 months, the participant is eligible provided
                appropriate treatment according to institutional standard of care is ensured.
  -      ",1476145970,,,,,,,,,,,,,,,,,,,,,,,,,,
  -NCT02392507,Phase 2,Eli Lilly and Company,Industry,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of NabÂ®-Paclitaxel (AbraxaneÂ®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",1,18,150,,,include,,,,,include,,,,,,,,,,,exclude,1800,exclude,12,,,"
  +      "
  +NCT02392507,Phase 2,Eli Lilly and Company,Industry,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab-Paclitaxel (Abraxane) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",1,18,150,,,include,,,,,include,,,,,,,,,,,exclude,1800,exclude,12,,,"
           Inclusion Criteria:
   
             -  Have histologically or cytologically confirmed squamous NSCLC.
  
positive.code: 
           11. Patients with known and documented EGFR mutation who have not received an EGFR
               inhibitor.
        ",1476145970,,,,,,,,,,,,,,,,,,,,,,,,,,
  NCT01630733,Phase 3,OncoGenex Technologies,Industry,"A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",2,18,150,include,include,include,,,,,include,,,,,,,require,,,,require,,,,require,,"
          Inclusion Criteria:
  
            1. Patients must have a histologically or cytologically confirmed, unresectable,
               advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLC
  
            2. Males or females â‰¥ 18 years of age at screening.
  
            3. Life expectancy of > 12 weeks from screening, according to the investigator's
               assessment.
  
negative.code:              treating institution's identity is provided in order to ensure that the current
               (within 365 days) date of institutional review board approval for this study has been
               entered in the system
        "
  NCT02438722,Phase 2/Phase 3,Southwest Oncology Group,Other,"A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)",2,0,150,include,include,include,,include,include,include,,,,,require,,,require,,,,exclude,1800,exclude,12,exclude,1800,"
          Inclusion Criteria:
  
  